Thromb Haemost 2016; 115(05): 950-959
DOI: 10.1160/TH15-08-0638
Coagulation and Fibrinolysis
Schattauer GmbH

A novel ELISA-based diagnosis of acquired von Willebrand disease with increased VWF proteolysis

Antoine Rauch
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
2   INSERM UMR 1011, Univ Lille 2, Institut Pasteur de Lille, Lille, France
,
Claudine Caron
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
,
Flavien Vincent
2   INSERM UMR 1011, Univ Lille 2, Institut Pasteur de Lille, Lille, France
3   Département de Cardiologie, CHU Lille, Lille, France
,
Emmanuelle Jeanpierre
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
,
Catherine Ternisien
4   Hématologie Biologique, CHU Nantes, Nantes, France
,
Pierre Boisseau
5   Laboratoire de génétique moléculaire, CHU Nantes, Nantes, France
,
Christophe Zawadzki
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
2   INSERM UMR 1011, Univ Lille 2, Institut Pasteur de Lille, Lille, France
,
Edith Fressinaud
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
,
Annie Borel-Derlon
6   Hématologie Biologique, Hôpital de la côte de Nacre, CHU Caen, Caen, France
,
Sylvie Hermoire
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
,
Camille Paris
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
,
Cécile Lavenu-Bombled
7   Hématologie Biologique, Hôpital Lariboisière, AP-HP, Paris, France
,
Agnès Veyradier
8   Inserm, UMR_S 1176, Univ. Paris-Sud, Université Paris-Saclay, Le Kremlin-Bicêtre, France
,
Alexandre Ung
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
,
André Vincentelli
2   INSERM UMR 1011, Univ Lille 2, Institut Pasteur de Lille, Lille, France
3   Département de Cardiologie, CHU Lille, Lille, France
,
Eric Van Belle
2   INSERM UMR 1011, Univ Lille 2, Institut Pasteur de Lille, Lille, France
3   Département de Cardiologie, CHU Lille, Lille, France
,
Peter J. Lenting
9   INSERM Unit 770, Le Kremlin-Bicetre, Val-de-Marne, France
,
Jenny Goudemand
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
2   INSERM UMR 1011, Univ Lille 2, Institut Pasteur de Lille, Lille, France
,
Sophie Susen
1   Département d'Hématologie Transfusion, CHU Lille, Lille, France
2   INSERM UMR 1011, Univ Lille 2, Institut Pasteur de Lille, Lille, France
› Author Affiliations
Further Information

Publication History

Received: 10 August 2015

Accepted after major revision: 05 January 2016

Publication Date:
06 December 2017 (online)

Zoom Image

Summary

Von Willebrand disease-type 2A (VWD-2A) and acquired von Willebrand syndrome (AVWS) due to aortic stenosis (AS) or left ventricular assist device (LVAD) are associated with an increased proteolysis of von Willebrand factor (VWF). Analysis of VWF multimeric profile is the most sensitive way to assess such increased VWF-proteolysis. However, several technical aspects hamper a large diffusion among routine diagnosis laboratories. This makes early diagnosis and early appropriate care of increased proteolysis challenging. In this context of unmet medical need, we developed a new ELISA aiming a quick, easy and reliable assessment of VWF-proteolysis. This ELISA was assessed successively in a LVAD-model, healthy subjects (n=39), acquired TTP-patients (n=4), VWD-patients (including VWD-2A(IIA), n=22; VWD-2B, n=26; VWD-2A(IIE), n=21; and VWD-1C, n=8) and in AVWS-patients (AS, n=9; LVAD, n=9; and MGUS, n=8). A standard of VWF-proteolysis was specifically developed. Extent of VWF-proteolysis was expressed as relative percentage and as VWF proteolysis/VWF:Ag ratio. A speeddependent increase in VWF-proteolysis was assessed in the LVAD model whereas no proteolysis was observed in TTP-patients. In VWDpatients, VWF-proteolysis was significantly increased in VWD-2A(IIA) and VWD-2B and significantly decreased in VWD-2A(IIE) versus controls (p< 0.0001). In AVWS-patients, VWF-proteolysis was significantly increased in AS- and LVAD-patients compared to controls (p< 0.0001) and not detectable in MGUS-patients. A significant increase in VWFproteolysis was detected as soon as three hours after LVAD implantation (p< 0.01). In conclusion, we describe a new ELISA allowing a rapid and accurate diagnosis of VWF-proteolysis validated in three different clinical situations. This assay represents a helpful alternative to electrophoresis-based assay in the diagnosis and management of AVWS with increased VWF-proteolysis.

Supplementary Material to this article is available online at www.thrombosis-online.com.